- News & Features
People who are controlling their rheumatoid arthritis with an anti-tumor necrosis factor (anti-TNF) drug may get sicker if they switch to a different one, researchers for AbbVie say.
Two leaders in the field of rheumatology discussed the most influential studies that have been done and issues that have come to the forefront this year: Apremilast, a new drug approved for psoriatic arthritis, the rise of biosimilar drugs, and a new way of thinking about immune dysfunction.
Keeping your joints and body healthy should not be sacrificed because of a fear of needles.
Ms. Meniscus advises a woman who is being switched from auto-injectors to infusion therapy.